Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04113122

Senescence and the Early Ageing Phenotype After Chemotherapy for Testicular Cancer: the SEA-CAT Study

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
192 (estimated)
Sponsor
University Medical Center Groningen · Academic / Other
Sex
Male
Age
18 Years – 50 Years
Healthy volunteers
Not accepted

Summary

Cisplatin-combination chemotherapy causes inevitably DNA damage by platinum-DNA adduct formation of both tumor cells but also healthy cells. It therefore stands to reason that testicular cancer treatment causes an increased burden of senescent cells, which causes upregulation of the SASP resulting in a pro-inflammatory phenotype. The investigators hypothesize that this may be an important mechanism behind development of late effects and an early ageing phenotype after treatment for testicular cancer.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTSkin biopsyA 4 mm skin biopsy will be performed at the upper leg of the patient. Before the skin biopsy local anesthesia is applied subcutaneously. In these skin biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels in the skin biopsies.
DIAGNOSTIC_TESTSubcutaneous fat biopsyAn abdominal subcutaneous fat biopsy will be performed 7-10 cm on the right side of the umbilicus. Before the fat biopsy local anesthesia is applied subcutaneously. An amount of 30 mg fat tissue will be collected using needle aspiration. In these fat biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels (ICP-MS), adipocytokines (leptin, adiponectin, interleukin-6, PAI-1, TNF-α), p53 activation indirectly by measuring p21 or mdm2 expression using immunohistochemistry, microRNA regulation of insulin signaling in adipose tissue: miR-103, miR-107, miR-29.

Timeline

Start date
2019-02-09
Primary completion
2026-09-01
Completion
2026-09-01
First posted
2019-10-02
Last updated
2024-12-13

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT04113122. Inclusion in this directory is not an endorsement.